Home/Recalls/FDA-D-0379-2026
FDA DrugsClass II

Semaglutide, For Rx compounding use only, packaged in a) 1g, NDC 84385-106-01; b...

Published: March 11, 2026Recall ID: D-0379-2026Category: drugsCountry: US

Reason for Recall / Hazard

CGMP Deviations This recall has been initiated due to failing to complete process validation and bacterial endotoxin method validation before distribution

Product Description & Identification

Semaglutide, For Rx compounding use only, packaged in a) 1g, NDC 84385-106-01; b) 5g, NDC 84385-106-02; c) 10g, NDC 84385-106-06; d) 25g, NDC 84385-106-03; d) 50g, NDC 84385-106-04 Manufacturer: Harbin Jixianglong Biotech Co., Ltd., North of Baoan Road, East of Changqing Street, Limin Development Zone, Harbin, China

Additional Source Details

FieldValue
CityHaerbin
StateN/A
Event id98438
Address 1North Of Baoan Road, East Of Changqing Street
Address 2Hulan District
Code infoLot #: CP-030-20250711, Exp. Date Jul. 24th, 2027
Postal codeN/A
Report date20260311
Product typeDrugs
Product quantityN/A
Reason for recallCGMP Deviations This recall has been initiated due to failing to complete process validation and bacterial endotoxin method validation before distribution
Voluntary mandatedVoluntary: Firm initiated
Recall initiation date20260213
Initial firm notificationE-Mail
Center classification date20260302

Overview

  • Recalling FirmHarbin Jixianglong Biotech Co., Ltd.
  • StatusOngoing
  • Risk LevelClass II
  • DistributionNationwide within the United States
Official Agency Alert